Patritumab Deruxtecan: TUXEDO-3 Trial in Leptomeningeal Metastasis
- An antibody-drug conjugate targeting HER3, patritumab deruxtecan, has demonstrated encouraging results in patients with leptomeningeal metastatic disease.
- The study focused on patients with leptomeningeal metastatic disease originating from various solid tumors.
- Further research is needed to fully evaluate the efficacy and safety of patritumab deruxtecan in treating leptomeningeal metastatic disease and to determine its potential impact on long-term survival.
Patritumab deruxtecan offers a glimmer of hope. The TUXEDO-3 trial’s phase 2 results reveal promising 3-month overall survival rates for patients battling leptomeningeal metastatic disease. As detailed in the article, this HER3-targeting antibody-drug conjugate shows potential against tumors. Researchers focused on patients with leptomeningeal metastases from various solid tumors. The study, a highlight at the 2025 ASCO Annual Meeting, underscores the importance of innovative treatments. news Directory 3 reports this breakthrough finding. This progress marks a crucial step toward improved outcomes. Further studies are planned to explore long-term benefits. Discover what’s next for this promising therapy.
HER3 Antibody-Drug Combo shows Promise for Leptomeningeal Metastatic Disease
Updated May 30, 2025
An antibody-drug conjugate targeting HER3, patritumab deruxtecan, has demonstrated encouraging results in patients with leptomeningeal metastatic disease. The findings, from cohort 3 of the phase 2 TUXEDO-3 trial, were presented at the 2025 ASCO Annual Meeting and published in Nature Medicine.
The study focused on patients with leptomeningeal metastatic disease originating from various solid tumors. The HER3-targeting antibody-drug conjugate showed promising 3-month overall survival rates in this patient population.
What’s next
Further research is needed to fully evaluate the efficacy and safety of patritumab deruxtecan in treating leptomeningeal metastatic disease and to determine its potential impact on long-term survival.